Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan

ABSTRACT: Purpose: Patients with hereditary transthyretin (ATTRv) amyloidosis experience progressive degeneration of the somatic and peripheral nervous system that can impair ambulation, autonomy, and quality of life (QOL). Tafamidis meglumine (tafamidis) is the first pharmacotherapy approved to sl...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Hiroaki Konishi, PharmD, Hajime Abe, MD, PhD, Noriko Matsumoto, Yutaka Endo, Yoshiki Sekijima, MD, PhD, Mitsuharu Ueda, MD, PhD, Yukio Ando, MD, PhD
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2025-01-01
Reeks:	Current Therapeutic Research
Onderwerpen:	Efficacy Hereditary transthyretin amyloidosis Japan Postmarketing surveillance Safety Tafamidis meglumine
Online toegang:	http://www.sciencedirect.com/science/article/pii/S0011393X25000189
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!